secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLIFE SOLUTIONS INC (BLFS)
CIK:        0000834365
Form:       8-K
Filed at:   2024-12-20T23:59:59+00:00
Accession:  0001628280-24-052235
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioLife Solutions appoints Tony J. Hunt (Repligen Chairman) to board effective Jan 2, 2025
--------------------------------------------------------------------------------

- Tony J. Hunt, Executive Chairman of Repligen (Nasdaq: RGEN), appointed to BioLife board.
- Appointment increases board size to six members; Hunt qualifies as independent under Nasdaq rules.
- Hunt previously served as Repligen CEO (2015-2024) and President of Bioproduction at Life Technologies.
- He will serve on the Audit Committee and receive standard non-employee director compensation.
- Board cites Hunt's bioprocessing expertise to support BioLife's focus on cell and gene therapy tools.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/834365/000162828024052235/0001628280-24-052235-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/834365/000162828024052235/blfs-20241216.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-052235

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer